Malin Corp PLC - Dublin-based investor in life sciences companies - Notes announcement from Nasdaq-listed Poseida Therapeutics Inc of its entry into a strategic collaboration and licence agreement with Roche Holding AG, for the development of allogeneic CAR-T therapies directed towards hematologic malignancies.
Poseida will receive USD110 million upfront, and can fain an additional USD110 million in near-term milestones and other payments.
Current stock price: EUR4.15
12-month change: down 38%
By Dayo Laniyan; email@example.com
Copyright 2022 Alliance News Limited. All Rights Reserved.